IDL Diagnostics AB (FRA:80R) Debt-to-EBITDA : (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:80R IDL Diagnostics AB FRA:80R
54 GF Score
Price €0.02
GF Value €0.03
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is IDL Diagnostics AB Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

IDL Diagnostics AB's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €0.21 Mil. IDL Diagnostics AB's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2026 was €0.89 Mil. IDL Diagnostics AB's annualized EBITDA for the quarter that ended in Jun. 2026 was €-0.36 Mil. IDL Diagnostics AB's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 was -3.08.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for IDL Diagnostics AB's Debt-to-EBITDA or its related term are showing as below:

FRA:80R' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.06   Med: -1.25   Max: 4.88
Current: -3.06

During the past 13 years, the highest Debt-to-EBITDA Ratio of IDL Diagnostics AB was 4.88. The lowest was -3.06. And the median was -1.25.

FRA:80R's Debt-to-EBITDA is ranked worse than
100% of 118 companies
in the Medical Diagnostics & Research industry
Industry Median: 2.475 vs FRA:80R: -3.06

IDL Diagnostics AB  (FRA:80R) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


IDL Diagnostics AB Debt-to-EBITDA Related Terms


IDL Diagnostics AB Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for IDL Diagnostics AB's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

IDL Diagnostics AB Debt-to-EBITDA Chart

IDL Diagnostics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

IDL Diagnostics AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

FRA:80R vs TMO, DHR, NTRA: Debt-to-EBITDA Comparison

For the Diagnostics & Research subindustry, IDL Diagnostics AB's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


IDL Diagnostics AB Debt-to-EBITDA vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, IDL Diagnostics AB's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where IDL Diagnostics AB's Debt-to-EBITDA falls into.


FRA:80R
54GF Score
IDL Diagnostics AB FRA:80R
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

IDL Diagnostics AB Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

IDL Diagnostics AB's Debt-to-EBITDA for the fiscal year that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.20291826088732 + 1.0195788265522) / -0.72864182903926
=-1.68

IDL Diagnostics AB's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2026 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.20506046767083 + 0.89344547527275) / -0.35708719498108
=-3.08

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2026) EBITDA data.

Is IDL Diagnostics AB (FRA:80R) Overvalued in 2026?

Based on GuruFocus' analysis, IDL Diagnostics AB stock appears to be undervalued. The current stock price of €0.02 is trading 26.7% below its estimated GF Value™ of €0.03. GuruFocus considers IDL Diagnostics AB to be Modestly Undervalued.

Key valuation signals for FRA:80R:

  • Debt-to-EBITDA:
  • GF Value™: €0.03 vs. price of €0.02 (26.7% below fair value)
  • GF Score™: 54/100 with 2 warning signs

No single metric tells the full story. See the FRA:80R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


IDL Diagnostics AB Business Description

Other Exchanges IDLDX:Sweden
Address Karlsbodavagen 39, Bromma, Stockholm, SWE, 168 67
IDL Diagnostics AB is a Swedish company that develops and markets blood and urine sample tests. It specializes in oncology and bacteriology. The company has a broad product portfolio, is used in healthcare, and is established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1 and cytokeratins, to support the treatment of cancers such as breast, prostate, and bladder cancers.
54GF Score

Get the complete analysis for FRA:80R

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.02
Price
€0.03
GF Value